Attached files

file filename
EX-3.2 - EXHIBIT 3.2 - SERA PROGNOSTICS, INC.tm2122556d1_ex3-2.htm
EX-3.1 - EXHIBIT 3.1 - SERA PROGNOSTICS, INC.tm2122556d1_ex3-1.htm

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 19, 2021

 

SERA PROGNOSTICS, INC.

 

(Exact name of registrant as specified in its charter)

 

Delaware   021-169017   26-1911522
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

2749 East Parleys Way, Suite 200
Salt Lake City, Utah

  84109
(Address of principal executive offices)   (zip code)

 

Registrant’s telephone number, including area code: (801) 990-0520

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading
Symbol(s)

 

Name of each exchange
on which registered

Class A Common Stock, $0.0001 par value per share   SERA   The Nasdaq Global Market

 

 

 

 

 

Item 5.03              Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

Amendment and Restatement of Certificate of Incorporation

 

On July 19, 2021, Sera Prognostics, Inc. (the “Company”) filed its seventh amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of its initial public offering (the “IPO”) of common stock. The Company’s board of directors and stockholders previously approved the Restated Certificate effective as of and contingent upon the closing of the IPO.

 

A copy of the Restated Certificate is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

 

Amendment and Restatement of Bylaws

 

The Company also adopted restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO. The Company’s board of directors and stockholders previously approved the Restated Bylaws effective as of and contingent upon the closing of the IPO.

 

A copy of the Restated Bylaws is attached hereto as Exhibit 3.2 and is incorporated herein by reference.

 

Item 8.01.             Other Events.

 

On July 19, 2021, the Company completed its initial public offering of 4,687,500 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions.

 

Item 9.01              Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
3.1   Amended and Restated Certificate of Incorporation of Sera Prognostics, Inc.
3.2   Restated Bylaws of Sera Prognostics, Inc.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  SERA PROGNOSTICS, INC.
     
  By: /s/ Gregory C. Critchfield, M.D., M.S.
    Gregory C. Critchfield, M.D., M.S.
    Chief Executive Officer

 

Date: July 20, 2021